Metastasis of skin squamous cell carcinoma in renal transplant recipient: epidemiological, clinical, histopathological and evolution

Abstract

Squamous cell carcinoma (SCC) is the most common skin malignancy in renal transplant recipients (RTR) due to immunosuppression. Comparing to the general population, they present higher numbers of lesions, relapses, and metastases, as well as developing early and severe tumors. Justification: considering the increase in kidney transplant procedures in Brazil, it is necessary to obtain detailed data on epidemiological, clinical, and histopathological characteristics of SCC that evolve with metastasis. Determining biomarkers linked to the worst prognosis will allow a better therapeutic approach. Objectives: to characterize the clinical, epidemiological, histopathological profiles of Brazilian RTR with primary skin SCC that evolves to metastasis, attended at the Dermatological Consultation of solid organ transplant recipients at the Department of Dermatology of UNIFESP-EPM. To compare the obtained data with immunocompetent patients who had metastatic SCC. The findings will be also compared to data from the World literature, in order to establish similarities. Material and methods: it is a cross-sectional retrospective cohort study complemented with histopathological analysis to establish the clinical-pathological correlation of skin SCCs that evolved with metastasis, in RTR and immunocompetent individuals. From the analysis of medical records, we will collect clinical, epidemiological, and evolutionary data. From the histopathological analysis, using hematoxylin-eosin stain, the neoplasia will be classified according to the criteria of Broders and the World Health Organization. Furthermore, other histological findings will be analyzed and accounted for. Method of analysis of the expected results and impacts: analysis through the correlation between the data obtained and the parameters studied, in order to determine the profile of the patient at risk. Establish parameters that will be useful as biomarkers of metastatic SCC and guide preventive therapies. (AU)